New Delhi: The Centre has invited fresh applications under the Production Linked Incentive Scheme for Promoting Domestic Manufacturing of Medical Devices (PLI-MD), which has now been extended up to 2035 – 2036.
Under the new guidelines, minimum sales threshold requirement to claim incentive has been discontinued, while minimum investment requirement has also been trimmed and made more investor friendly.
The applicants can submit applications through an online portal, which would be operational in the next 10 days and can apply under mulitple segments including medical consumables, disposables and implants, Critical components and high-end medical devices.
Approximately Rs 2700 Cr outlay available under the Scheme will be utilized for the purpose, the Department of Pharmaceuticals said in a release.
The PLI-MD scheme launched in 2020 -2021, has contributed to domestic manufacturing of over 60 high end medical devices and components, including X-ray tubes and detectors, 1.5T MRI, LINAC, CT scanners, mammography machines, Cathlab, orthopaedic and cardiac implants, dialyzers etc till date. The scheme has resulted in production valued at over ₹16,000 crore, the ministry said.
“PLI-MD 2.0 aims to fulfil the vision of Atmanirbhar Bharat and Make in India, develop indigenous supply chains, attract investment, generate employment, improve quality of Made in India devices, reduce price of medical devices, and enhance India’s global competitiveness in high-end medical technologies. The objective of the Scheme is to promote deep manufacturing of medical devices, as well as manufacturing of high-end medical equipment like 3T MRI, PET-CT, Ultrasound probes & consoles, high-throughput IVD analyzers etc which are currently not being manufactured in the country,” it added in a public statement.
The Association of Indian Medical Device Industry (AiMeD) welcomed the move.
Rajiv Nath, AiMed Forum Director, said, “The Association of Indian Medical Device Industry (AiMeD) warmly welcomes the Government’s continued commitment to strengthening domestic medical device manufacturing through the Production Linked Incentive (PLI) Scheme(V2.0), which aims to boost local manufacturing and attract investments into India’s medical technology sector.
This is a significant step towards building a globally competitive, self-reliant MedTech ecosystem under the Make in India vision. “
Himanshu Baid, Managing Director, Poly Medicure Ltd praised the move to simplify key guidelines and the focus on critical component manufacturing.
He said, “The enhanced focus on critical component manufacturing is particularly significant, as components are the backbone of the MedTech industry. Developing a robust indigenous component ecosystem will help reduce import dependence, strengthen supply chain resilience and enable deeper domestic manufacturing.
“Equally encouraging are the investor-friendly reforms introduced to improve Ease of Doing Business. Simplification of scheme guidelines, discontinuation of the minimum sales threshold requirement for claiming incentives and reduction in the minimum investment requirement will make the scheme more accessible, flexible and attractive to both existing manufacturers and new investors. These changes reflect the Government’s responsiveness to industry requirements and will encourage wider participation and fresh investments.”
